← Back to Clinical Trials
Recruiting NCT07431554

NCT07431554 Effect of Acute Hypoxia on RIght VEntRicular Function in HAPE.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07431554
Status Recruiting
Phase
Sponsor Mona Lichtblau
Condition Altitude Hypoxia
Study Type INTERVENTIONAL
Enrollment 18 participants
Start Date 2026-03-17
Primary Completion 2030-01

Trial Parameters

Condition Altitude Hypoxia
Sponsor Mona Lichtblau
Study Type INTERVENTIONAL
Phase N/A
Enrollment 18
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2026-03-17
Completion 2030-01
Interventions
Normobaric Hypoxia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

More and more people are engaging in sports in the mountains, including individuals with heart or lung diseases. At the same time, such diseases are becoming more common in Switzerland. At high altitude, less oxygen is available, which places stress on the body-particularly on the heart, which has to pump blood through the lungs. How the heart, especially the right ventricle, in people with past HAPE responds to this stress is still not well understood. Therefore, this study investigates how the heart responds to simulated altitudes of 2,500 m and 4,000 m, both at rest and during light physical activity in patients with past HAPE. The primary objective is to assess how right ventricular function changes under conditions of reduced oxygen availability. In addition, vital signs, changes in blood gases, oxygen levels in blood and tissue and shortness of breath are assessed. The "altitude" is simulated using a special gas mixture that participants inhale. Participants undergo three altitude conditions (490, 2,500, and 4,000 m above sea level). The order of the altitude conditions is assigned at random. The aim is to better understand how the right ventricle and other parameters respond to low-oxygen conditions and how affected patients can be better supported in the future.

Eligibility Criteria

Inclusion Criteria: * Signed informed consent * Diagnosed or suspicion of past HAPE * 18-80 years (age group young: 18-39.99 years / age group older: 40-80 years) * All sex and genders * Living \<800m and without altitude exposure \> 2500 m and \> 24h within the last three weeks Exclusion Criteria: * \<18, \>80 years old * Any other diagnosed cardiopulmonary condition * Other clinically significant severe concomitant disease states (e.g. renal, hepatic dysfunction, etc.) * Inability to follow the procedures of the study due to language problems, psychological neurological disorders or orthopaedic disorders * Participants permanently living \>800m and altitude exposure \> 2500 m and \>24h within the last three weeks * Pregnancy: Participants will be asked if pregnant or not, no screening for undetected pregnancy * Lactating women * Participation in other study with active treatment

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology